American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hyperandrogenic disorders

Endocrine Practice

Volumn 7, Issue 2, 2001, Pages 121-134

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BROMOCRIPTINE; CABERGOLINE; CIMETIDINE; CLOMIFENE CITRATE; CYPROTERONE ACETATE; DESOGESTREL; DEXAMETHASONE; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN; GONADORELIN AGONIST; INSULIN; KETOCONAZOLE; METFORMIN; NAFARELIN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PREDNISONE; PROLACTIN; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; THIAZOLE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG;

ACNE; ADRENAL SUPPRESSION; ARTICLE; CLINICAL EXAMINATION; CLINICAL PRACTICE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FEMALE INFERTILITY; HEADACHE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIVER TOXICITY; MALE; MALE TYPE ALOPECIA; MEDICAL SOCIETY; METABOLIC DISORDER; OSTEOLYSIS; PRACTICE GUIDELINE; SIDE EFFECT; SYMPTOMATOLOGY; VIRILIZATION; WEIGHT REDUCTION; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; OVULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

HYPERANDROGENISM; ANDROGENS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; OVULATION;

EID: 0042884287     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Androgens and women's health
2. Acne and hyperandrogenism
3. Hormonal correlates of acne and hirsutism
4. Role of androgens in the developmental biology of the pilosebaceous unit
5. The role of androgen excess in acne
6. The menstrual cycle and plasma testosterone levels in women with acne
7. Prevalence of polycystic ovaries in women with acne
8. Hypertrichosis portrayed in art
9. Hirsutism, race and testosterone levels: Comparison of East Asians and Euroamericans
10. Bioactive and peripheral androgens in prepubertal simple hypertrichosis
11. A study of body hair density and distribution in normal women
12. Clinical assessment of body hair growth in women
13. Hirsutism: Implications, etiology, and management
14. Selected aspects of polycystic ovarian disease
15. 3 Alpha, 17 beta-androstanediol glucuronide in plasma: A marker of androgen action in idiopathic hirsutism
16. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia
17. Clinical evaluation of androgen excess
18. Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women
19. The relation between plasma testosterone levels and the lengths of phases of the menstrual cycle
20. Testosterone levels in female partners of infertile couples: Relationship between androgen levels in the woman, the male factor, and the incidence of pregnancy
21. Polycystic ovary syndrome: Clinical perspectives and management
22. The polycystic ovary. I. Clinical and histological findings
23. Recurrent early miscarriage and polycystic ovaries
24. Obesity, lipids, cardiovascular risk, and androgen excess
25. Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus
26. The relationship of serum androgens and ovulatory status to blood pressure in reproductive-age women
27. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
28. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome
29. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
30. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
31. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones
32. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens
33. Clinical signs of androgen excess as risk factors for coronary artery disease
34. The cardiovascular dysmetabolic syndrome
35. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with the polycystic ovary syndrome (PCOS)
36. Preventive reproductive medicine
37. Consequences of hyperandrogenism during adolescence on the ovarian function of the adult female
38. The inheritance of polycystic ovarian disease and possible relationship to premature balding
39. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity
40. Central adiposity and increased risk of coronary artery disease mortality in older women
41. Polycystic ovaries-a common finding in normal women
42. A case of bilateral dermoid cysts, insulin resistance, and polycystic ovarian disease: Association of ovarian tumors with polycystic ovaries with review of the literature
43. Utilization of commercial laboratory results in management of hyperandrogenism in women
44. Serum testosterone levels and reference ranges in reproductive-age women
45. Obesity regulates bioavailable testosterone levels in women with or without polycystic ovary syndrome
46. Hyperandrogenism and female infertility
47. Luteinizing hormone: Its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase
48. Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data
49. The prognostic value of acute adrenal suppression and stimulation tests in hyperandrogenic women
50. Effect of dexamethasone on serum cortisol and androgen levels in hirsute patients
51. Ovarian and adrenal contributions to peripheral androgens in hirsute women
52. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome
53. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome
54. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers
55. Lipoprotein lipids in women with androgen excess: Independent associations with increased insulin and androgen
56. Prevalence of adrenal androgen excess in PCOS
57. Effect of prednisone on plasma testosterone levels and on duration of phases of the menstrual cycle in hyperandrogenic women
58. Acne and hyperandrogenism: Impact of lowering androgen levels with glucocorticoid treatment
59. Glucocorticoid therapy in hyperandrogenism
60. The treatment of hyperandrogenism with oral contraceptives
61. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone
62. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive
63. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
64. Treatment of hirsutism with spironolactone
65. Treatment of androgenic disorders
66. Spironolactone in combination drug therapy for unresponsive hirsutism
67. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism
68. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
69. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: Clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up
70. Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism
71. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
72. Insulin and ovarian androgen excess
73. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
74. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
75. Metformin effects on clinical features, endocrine and metabolic profiles, randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
76. Contrast media and metformin: Guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media
77. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease
78. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome
79. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: A pilot study
80. Combined oral contraceptives and gonadotropin releasing hormone agonistic analogs in polycystic ovary syndrome: Clinical and experimental studies
81. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome
82. An endocrine approach to obesity
83. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
84. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss
85. 17 Alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss